These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I; Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886 [TBL] [Abstract][Full Text] [Related]
23. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485 [TBL] [Abstract][Full Text] [Related]
24. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390 [TBL] [Abstract][Full Text] [Related]
25. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Infante J; Rodríguez E; Combarros O; Mateo I; Fontalba A; Pascual J; Oterino A; Polo JM; Leno C; Berciano J Neurosci Lett; 2006 Mar; 395(3):224-6. PubMed ID: 16298482 [TBL] [Abstract][Full Text] [Related]
26. Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients. Ponzo V; Di Lorenzo F; Brusa L; Schirinzi T; Battistini S; Ricci C; Sambucci M; Caltagirone C; Koch G Mov Disord; 2017 May; 32(5):750-756. PubMed ID: 28186666 [TBL] [Abstract][Full Text] [Related]
27. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse. Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786 [TBL] [Abstract][Full Text] [Related]
28. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001 [TBL] [Abstract][Full Text] [Related]
29. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Trinh J; Amouri R; Duda JE; Morley JF; Read M; Donald A; Vilariño-Güell C; Thompson C; Szu Tu C; Gustavsson EK; Ben Sassi S; Hentati E; Zouari M; Farhat E; Nabli F; Hentati F; Farrer MJ Neurobiol Aging; 2014 May; 35(5):1125-31. PubMed ID: 24355527 [TBL] [Abstract][Full Text] [Related]
30. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881 [TBL] [Abstract][Full Text] [Related]
31. [Clinical features of LRRK2-associated Parkinson's disease]. Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811 [TBL] [Abstract][Full Text] [Related]
32. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Zuo L; Motherwell MS Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870 [TBL] [Abstract][Full Text] [Related]
33. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release. Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470 [TBL] [Abstract][Full Text] [Related]
34. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation. Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903 [TBL] [Abstract][Full Text] [Related]
36. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. Li C; Ting Z; Qin X; Ying W; Li B; Guo Qiang L; Jian Fang M; Jing Z; Jian Qing D; Sheng Di C Mov Disord; 2007 Dec; 22(16):2439-43. PubMed ID: 17960808 [TBL] [Abstract][Full Text] [Related]
37. Exploring Caenorhabditis elegans as Parkinson's Disease Model: Neurotoxins and Genetic Implications. da Silva LPD; da Cruz Guedes E; Fernandes ICO; Pedroza LAL; da Silva Pereira GJ; Gubert P Neurotox Res; 2024 Feb; 42(1):11. PubMed ID: 38319410 [TBL] [Abstract][Full Text] [Related]
38. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757 [TBL] [Abstract][Full Text] [Related]
39. Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Gosal D; Ross OA; Wiley J; Irvine GB; Johnston JA; Toft M; Mata IF; Kachergus J; Hulihan M; Taylor JP; Lincoln SJ; Farrer MJ; Lynch T; Mark Gibson J Parkinsonism Relat Disord; 2005 Sep; 11(6):349-52. PubMed ID: 16102999 [TBL] [Abstract][Full Text] [Related]
40. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Alcalay RN; Mejia-Santana H; Tang MX; Rosado L; Verbitsky M; Kisselev S; Ross BM; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner C; Mickel SF; Andrews HF; Waters CH; Fahn S; Cote LJ; Frucht SJ; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Caccappolo E; Ottman R; Clark LN; Marder KS Arch Neurol; 2009 Dec; 66(12):1517-22. PubMed ID: 20008657 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]